# Chlorambucil in Metastatic PDAC Patients Bearing a Germ Line DNA Defects Repair Mutations (SALE Trial)

> **NCT04692740** · PHASE2 · UNKNOWN · sponsor: **Michele Reni** · enrollment: 20 (actual)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** Chlorambucil, Oral, 2 Mg

## Key facts

- **NCT ID:** NCT04692740
- **Lead sponsor:** Michele Reni
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-18
- **Primary completion:** 2023-01-04
- **Final completion:** 2023-12
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2023-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04692740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04692740, "Chlorambucil in Metastatic PDAC Patients Bearing a Germ Line DNA Defects Repair Mutations (SALE Trial)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04692740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*